52X Stock Chart & Stats
€1.49
€0.00(0.00%)
At close: 4:00 PM EST
€1.49
€0.00(0.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €2.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€949.78K
Enterprise Value€363.38
Total Cash (Recent Filing)€2.08M
Total Debt (Recent Filing)€343.99M
Price to Earnings (P/E)―
Beta0.13
Next Earnings
Nov 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.23
Shares Outstanding30,263,191
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.92
Price to Sales (P/S)1.28
P/FCF Ratio-8.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.13
Revenue Forecast (FY)€25.85M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthPositive trailing-twelve-month revenue growth indicates that customer demand for the company’s development and manufacturing services is expanding. If sustained, this growth can improve operating leverage, support investment in capabilities, and provide a stronger base for restoring profitability.
Gross MarginA gross margin of approximately 54% shows that the company’s services generate meaningful value above direct costs, despite recent compression. This provides an underlying economic base from which better cost control or higher utilization could support future earnings recovery.
CDMO Business ModelThe company operates across pharmaceutical development and manufacturing services, including analytical work, APIs, and finished dosage forms. This breadth can support multiple customer needs and deepen commercial relevance within regulated pharma and biotech markets over time.
Bears Say
Severe Profitability DeclineDeeply negative net and operating results show that the current cost structure is overwhelming gross profit, even with revenue growth and a positive gross margin. Persistent losses could restrict investment capacity, weaken the equity base, and delay a return to sustainable earnings.
Sustained Cash BurnOperating and free cash flow of roughly negative 110m indicate that the business is not currently converting operations into internally generated funding. Continued cash burn may require additional financing and could limit the company’s ability to fund development, capacity, or growth independently.
Higher LeverageDebt now exceeds equity and the equity cushion has contracted materially, consistent with loss-driven erosion. This weakens financial flexibility, increases the consequences of further losses, and may constrain capital allocation while the company works to restore profitability and cash generation.
Magle Chemoswed Holding AB News
52X FAQ
What was Magle Chemoswed Holding AB’s price range in the past 12 months?
Magle Chemoswed Holding AB lowest stock price was <€0.01 and its highest was €2.00 in the past 12 months.
What is Magle Chemoswed Holding AB’s market cap?
Magle Chemoswed Holding AB’s market cap is €949.78K.
When is Magle Chemoswed Holding AB’s upcoming earnings report date?
Magle Chemoswed Holding AB’s upcoming earnings report date is Nov 02, 2026 which is in 54 days.
How were Magle Chemoswed Holding AB’s earnings last quarter?
Magle Chemoswed Holding AB released its earnings results on Aug 12, 2026. The company reported -€0.074 earnings per share for the quarter.
Is Magle Chemoswed Holding AB overvalued?
According to Wall Street analysts Magle Chemoswed Holding AB’s price is currently Overvalued.
Does Magle Chemoswed Holding AB pay dividends?
Magle Chemoswed Holding AB does not currently pay dividends.
What is Magle Chemoswed Holding AB’s EPS estimate?
Magle Chemoswed Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Magle Chemoswed Holding AB have?
Magle Chemoswed Holding AB has 30,263,191 shares outstanding.
What happened to Magle Chemoswed Holding AB’s price movement after its last earnings report?
Magle Chemoswed Holding AB reported an EPS of -€0.074 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Magle Chemoswed Holding AB?
Currently, no hedge funds are holding shares in DE:52X
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Magle Chemoswed Holding AB
Magle Chemoswed Holding AB (publ), based in Malmö, Sweden, specializes in the research, development, and manufacturing of products within the pharmaceutical chemistry and technology sectors. The company's core activities include the process development and production of Active Pharmaceutical Ingredients (APIs), as well as the innovation and manufacturing of advanced wound care and diagnostic products, primarily leveraging its proprietary degradable starch microsphere technology. Its API portfolio features Warfarin sodium, used as an anticoagulant; Melperone hydrochloride, an antipsychotic agent; Isradipine, a calcium channel blocker for hypertension; Amantadine sulfate, for central nervous system disorders; and Benserazide hydrochloride, utilized with L-Dopa in Parkinson's disease treatment. Furthermore, Magle Chemoswed offers a range of medical devices for advanced wound care, surgical diagnostics, and drug delivery. These include EmboCept S, a microsphere-based device for vascular occlusion in liver and lung tumors; SmartGel, an innovative non-allergenic hydrogel derived from their microsphere platform; SmartPAN, a diagnostic tool for detecting pancreatic fluid leakage during surgical procedures; and EmboCept M, designed for managing benign prostatic hyperplasia. The company provides contract services to the pharmaceutical and medical device industries. Founded in 1944, Magle Chemoswed Holding AB (publ) operates as a subsidiary of Magle AB.
Technical Analysis
BioInvent International AB
―
Scandinavian ChemoTech AB Class B
―
Elicera Therapeutics AB
―
Spago Nanomedical AB
―
Cantargia AB
―